TwinTrader.com announces the publication of Breakout for DRRX; highlighting public companies on the move and what’s behind the surge.
Investors can view all of the Breakouts and other articles for free by visiting:
http://www.TwinTrader.com
“Durect Corp., a specialty pharmaceutical company, engages in developing pharmaceutical products based on proprietary drug delivery technology platforms. Its products under phase II clinical trials include POSIDUR, a release injectable to deliver bupivacaine, an off-patent anesthetic agent; TRANSDUR-Sufentanil, a transdermal sufentanil patch that uses TRANSDUR delivery system to deliver sufentanil, an opioid medication; and ELADUR, a transdermal bupivacaine patch…
“Durect announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY® and granted Priority Review. The FDA typically grants Priority Review to drug candidates that have the potential to demonstrate significant improvements compared to marketed products…
“Durect shares have traded within an ascending band since bottoming in early July. The stock has achieved strong momentum, consolidated, and then climbed through both its 50-day and 200-day moving averages, decisively. During this ascent, the RSI has never crossed the RSI(70) overbought level, which has given the stock further ammunition for another upward move...”
To read the entire article visit http://www.TwinTrader.com
Join the fastest growing investor community at:
http://www.stocknetworkonline.com/
TwinTrader LLC (TT) is not a registered broker-dealer and is not a registered investment advisor. No investor should base their investments decisions upon any act or omission of TT. TT makes no representations or warranties, and none may be relied upon. The purchase and sale of any securities must be made solely with the assistance of a registered broker-dealer and/or investment advisor. TT may, and you should assume that TT does, own shares in the companies profiled on this site. TT intends to sell its shares at times and as otherwise allowed by the securities laws which may negatively affect the performance of the stock price. TT affiliates, officers, directors and employees may have also bought or may buy shares in the companies profiled on this site and may sell, and profit from the sale of, such shares at any time. Except as required by the securities laws, TT will not advise when it or its affiliates, officers, directors and employees intend to sell and will not offer any opinion as to when others should sell. Any recent increase in volume or increase in stock price may be due to trading by TT or its affiliates, officers, directors and employees. TT will not be responsible for any gains or losses due to investing based on any opinions contained on this site. Receipt of the stock profiles, either via e-mail or directly from this site, is not in any way a solicitation or recommendation to buy or sell and should be used for information purposes only. Short-term trading can be extremely risky. As with any investment decision, careful research should be done before making any decision to invest.
TwinTrader.com is a Web site partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice. For the full disclaimer visit www.beaconequity.com/m.
Source: TwinTrader.com
TwinTrader.com
Scott Sanchez, (214)-317-5947
scott@twintrader.com
